Skip to content
sellWeak cluster of 410b5-1 plan

Michael J. McElhaugh sold $78k of ABUS

Interim President & CEO at Arbutus Biopharma Corp. 23,790 shares at an average of $3.28, traded Feb 4, 2025, filed Feb 5, 2025.

Warning score
29
Value
$78k
23,790 shares
Holdings after
1,481,003
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CEO
    +25
  • Trade size
    $78k at market
    +9
  • Share of holdings sold
    Sold 1.6% of holdings
    0
  • Cluster
    4 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -7.8%, 3m -8.4%, 6m -3.3%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ABUSOct 9, 2026 · close 4.22
Since filing Feb 5, 2025: +17.5%SPY +31.4% · excess -13.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001447028-25-000038, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 4, 2025SOpen-market sale
Common Shares10b5-1
-23,790$3.28$78k1,481,003Feb 5, 2025

Related signals

Other insiders at Arbutus Biopharma Corp and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
21Weak
ABUSsell 410b5-1
Arbutus Biopharma Corp
J. Christopher Naftzger
General Counsel and CCO
$37k
11,333 shares
-12%
23Weak
ABUSsell 410b5-1
Arbutus Biopharma Corp
Karen Sims
Chief Medical Officer
$64k
19,348 shares
-15%
30Weak
ABUSsell 410b5-1
Arbutus Biopharma Corp
David C Hastings
Chief Financial Officer
$73k
22,183 shares
-12%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Michael J. McElhaugh sold $78k of ABUS | InsiderTell